KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Bionano Genomics (BNGO) Long-Term Debt Issuances (2018 - 2023)

Bionano Genomics' Long-Term Debt Issuances history spans 3 years, with the latest figure at $80.0 million for Q4 2023.

  • For Q4 2023, Long-Term Debt Issuances changed N/A year-over-year to $80.0 million; the TTM value through Sep 2025 reached $80.0 million, down 0.94%, while the annual FY2024 figure was $18.0 million, 77.5% down from the prior year.
  • Long-Term Debt Issuances for Q4 2023 was $80.0 million at Bionano Genomics, up from $761000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $80.0 million in Q4 2023 and bottomed at -$14.1 million in Q4 2019.
  • The 3-year median for Long-Term Debt Issuances is $761000.0 (2020), against an average of $17.2 million.
  • The largest YoY upside for Long-Term Debt Issuances was 105.41% in 2020 against a maximum downside of 105.41% in 2020.
  • A 3-year view of Long-Term Debt Issuances shows it stood at -$14.1 million in 2019, then surged by 105.41% to $761000.0 in 2020, then surged by 10412.48% to $80.0 million in 2023.
  • Per Business Quant, the three most recent readings for BNGO's Long-Term Debt Issuances are $80.0 million (Q4 2023), $761000.0 (Q4 2020), and -$14.1 million (Q4 2019).